Unicycive Therapeutics Inc.

UNCY

We are a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative therapies to address significant unmet medical needs, with an initial focus on kidney disease. Founded in 2016, Unicycive was established to create a streamlined and efficient drug development platform capable of accelerating the advancement of promising therapies from discovery to c…

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$104M

EPS-$1.25

P/E-3.00

P/FCF-3.75

EV/EBITDA-1.32

FCF Yield–

Div. Yield1.05%

Net Debt/FCF2.2x

Unicycive Therapeutics Inc. intrinsic value

52-Week Range

$3.36$8.56

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$35M

▲ +27.7% YoY

Op. Margin

–

ROIC

-65.24%

▲ +448.5pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF (TTM)

-$28M

▼ -9.4% YoY

Op. Cash Flow (TTM)

-$28M

▼ -9.6% YoY

Net Debt

-$61M

Net Cash Position

Cash & Equiv.

$61M

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with UNCY

CompareIntrinsic value

RLYBRallybio Corporation

$15.90+0.25%62

ONCOOnconetix Inc.

$0.66+15.69%50

SLNSilence Therapeutics plc

$19.80+0.10%10

BTAIBioXcel Therapeutics, Inc.

$0.01-3.60%30

VCNXVaccinex, Inc.

$0.70-1.39%10

ELABPMGC Holdings Inc.

$1.92-1.03%20

QUCYQuantum Cyber N.V.

$0.74+2.62%10

LIPOLipella Pharmaceuticals Inc.

$0.00+0.00%25

Held by ETFs

UNCY is in 3 US ETFs. The largest of them, with UNCY's weight in each:

Unicycive Therapeutics (UNCY) in three numbers

Quality score: 10/100; Best check: net debt, -$61M. Weakest: return on capital, -65.2%.; Quality
Dividend (FY2024): $0.16; 4.36% yield, not raised in the latest year.; Dividends
P/E: -3.00; Negative: a loss over the last twelve months. Price to free cash flow -3.75.; Financials

Questions about Unicycive Therapeutics

Is Unicycive Therapeutics a high-quality business?

Unicycive Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 6 checks computed from SEC filings. Its best check is net debt at -$61M, and its weakest is return on capital at -65.2%. The Quality tab shows every check against its target.

Does Unicycive Therapeutics (UNCY) pay a dividend, and how much?

Yes. Unicycive Therapeutics (UNCY) pays a dividend: $0.16 per share for fiscal 2024, a dividend yield of 4.36% at the latest close. The Dividends tab has the full payment history and the safety score.

Source: 10-Q filed 12 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in UNCY's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing UNCY

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.